{
    "clinical_study": {
        "@rank": "119294", 
        "acronym": "LEADER", 
        "arm_group": [
            {
                "arm_group_label": "Levamlodipine Maleate (Xuanning)", 
                "description": "Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications"
            }, 
            {
                "arm_group_label": "Amlodipine Besylate (Norvasc)", 
                "description": "Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the effectiveness of levamlodipine maleate\n      (xuanning) is noninferior to amlodipine besylate (Norvasc) in treatment of hypertension in a\n      Chinese primary hypertension population."
        }, 
        "brief_title": "Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "It is a multicenter, prospective cohort study with large sample size. It is to evaluate the\n      effect on the incidence of cardiovascular and cerebrovascular endpoint events and blood\n      pressure control in hypertensive patients who use Levamlodipine Maleate (Xuanning) or\n      amlodipine besylate(Norvasc).Xuanning group and Norvasc group will recruit 5000 patients\n      respectively. Each site will recruit patients in chronological order\uff1bpatients who\n      participate will finish the two-year follow up(1,2,3,6,12,18,24 months after recruitment)\n      and relevant data will be recorded. Baseline data will be analyzed to evaluate the\n      equilibrium between two or more groups (such as the number of options). Logistic regression\n      and propensity scores (PS) would be used to match major indicators of effectiveness and\n      safety indicators using matching method baseline data."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  systolic pressure \u2265140mmHg or diastolic pressure \u226590mmHg or receiving\n             antihypertensive drug treatment\n\n          -  Patient himself/herself or his/her family member has already signed the informed\n             consent form\n\n          -  Patient is fit for use of Levamlodipine Maleate or amlodipine besylate\n\n          -  Age\u226545\n\n        Exclusion Criteria:\n\n          -  patient with secondary hypertension\n\n          -  patients who has suffered from myocardial infarction or stroke within the latest 3\n             months\n\n          -  patients who has obvious intelligence\u3001hearing and limb's activity disability\n\n          -  Patients with severe disease, with a life expectancy of less than two years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "100 eligible sites(including primary care clinic and tertiary hospitals) over the country\n        will participate. Each  center will collect patients who fit the recruitment standard in\n        chronological order."
            }
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844570", 
            "org_study_id": "LEADER"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Maleic acid", 
                "Amlodipine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100034"
                }, 
                "name": "Peking University First Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "Levamlodipine Maleate (Xuanning) or Amlodipine Besylate (Norvasc) for Treatment of Hypertension: A Comparative Effectiveness Research", 
        "overall_official": {
            "affiliation": "Department of Cardiology, Peking University First Hospital", 
            "last_name": "Yong Huo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Science and Technology", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "incidence of composite cardiovascular and cerebrovascular endpoints", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "quality of blood pressure control", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844570"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University First Hospital", 
            "investigator_full_name": "Yong Huo", 
            "investigator_title": "Professor of cardiovascular medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "incidence of adverse reaction", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "cost-effectiveness analysis", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Explore the optimal combination of drugs for the treatment of hypertension by Levamlodipine Maleate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Peking University First Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ministry of Science and Technology of the People\u00b4s Republic of China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Southern Medical University, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "CSPC Ouyi Pharmaceutical Co., Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Peking University First Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}